Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AVIR
- Price
- 2.71
- Stock movement up
- +0.02 (0.74%)
- Company name
- Atea Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 228.90M
- Ent value
- 162.87M
- Price/Sales
- -
- Price/Book
- 0.50
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -28.12%
- 3 year return
- -26.05%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AVIR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.50 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 84.46M |
| EPS (TTM) | -2.06 |
| FCF per share (TTM) | -1.50 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -312.00K |
| Operating income (TTM) | -200.50M |
| Net income (TTM) | -174.01M |
| EPS (TTM) | -2.06 |
| EPS (1y forward) | -1.58 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 98.46M |
| Net receivables | 0.00 |
| Total current assets | 486.91M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 490.96M |
| Accounts payable | 5.79M |
| Short/Current long term debt | 1.83M |
| Total current liabilities | 25.19M |
| Total liabilities | 32.44M |
| Shareholder's equity | 458.52M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -126.94M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -126.94M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -37.95% |
| Return on Assets | -35.44% |
| Return on Invested Capital | -37.88% |
| Cash Return on Invested Capital | -27.64% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.70 |
| Daily high | 2.74 |
| Daily low | 2.63 |
| Daily Volume | 327K |
| All-time high | 88.44 |
| 1y analyst estimate | 7.40 |
| Beta | 0.17 |
| EPS (TTM) | -2.06 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AVIR | S&P500 | |
| Current price drop from All-time high | -96.94% | -12.89% |
| Highest price drop | -97.00% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -83.19% | -11.07% |
| Avg time to new high | 41 days | 12 days |
| Max time to new high | 1050 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
228.90M
Marketcap category
Small-cap
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Employees
75
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
The following slide deck was published by Atea Pharmaceuticals, Inc.
May 14, 2024
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ETCompany ParticipantsJonae Barnes - Senior Vice...
February 29, 2024
iO Charts is a Seeking Alpha partnerNext page